This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Annexin Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Annexin Pharmaceuticals has a total shareholder equity of SEK6.3M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK11.8M and SEK5.5M respectively.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
SEK 0
Schuld
| Rente dekkingsratio | n/a |
| Contant | SEK 7.87m |
| Aandelen | SEK 6.35m |
| Totaal verplichtingen | SEK 5.47m |
| Totaal activa | SEK 11.81m |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: ANNX BTA's short term assets (SEK10.0M) exceed its short term liabilities (SEK5.5M).
Langlopende schulden: ANNX BTA's short term assets (SEK10.0M) exceed its long term liabilities (SEK1,000.0).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: ANNX BTA is debt free.
Schuld verminderen: ANNX BTA has no debt compared to 5 years ago when its debt to equity ratio was 1.2%.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: ANNX BTA has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Voorspelling contante baan: ANNX BTA is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.